US biotechnology company Altavant Sciences, which focuses on drug development for rare respiratory diseases, has appointed Howard M. Lazarus as CMO. Lazarus has over 20 years’ experience in drug development for pulmonary, vascular and interstitial diseases.
This book, originally published in France, investigates this growing international problem, its causes, and argues that recent developments can explain why fraudulent behaviour has become so prevalent.
Life operates on the nanometre scale. The fundamental processes of muscle action, reproduction, genetic inheritance, metabolism, and everything else that living things do, are what we now call ‘nano’. They are carried out by macromolecules within or near cells, with dimensions and distances measuring a few nanometres at most.
X.-J. Wang and M. Hong have managed to identify a suitable catalyst that was able to polymerise β-angelica lactone.
An international team of researchers has discovered a new biomarker that could be used to detect Alzheimer’s disease decades before symptoms emerge.
Antibodies taken from recovered patients or made in cell cultures are showing promise in treating Covid-19 patients.
With Covid-19 causing havoc around the world, the biopharmaceutical industry is playing a key role in the hunt for treatments and preventative vaccines, as well as donating expertise and goods to the treatment efforts.
Animal coronaviruses infect people quite frequently. After sampling a cave in Southern China for five years, scientists reported a coronavirus menagerie in its bat residents, including 11 similar to the SARS virus (PLOS Pathogens, doi:10.1371/journal.ppat.1006698).
DNA encoded libraries (DELs) may be used on purified protein targets to find ligands that bind, but that requires a purified sample of the protein, which can be difficult to obtain. Krusmark and co-workers at Purdue have established a way to use DELs on living cells.
Global pharma major AstraZeneca is collaborating with UK biotechnology company Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for cardiovascular, renal, metabolic and respiratory diseases.